Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Recovery & Repair

Pentadeca arginate (PDA)

Also known as PDA · Pentadeca arginate · Pentadecapeptide arginate · Pentadeca-arginate · BPC-157 arginate (claimed) · PDA peptide

Not approved — research use onlyWhat this means

Pentadeca arginate (PDA) is a commercial name with no peer-reviewed publication, PubChem record or registered trial located, so its exact identity and its relationship to BPC-157 are not established in primary sources.

US status
Not approved — research use only
Class
Commercially named peptide product of unverified composition (described in relation to BPC-157)
More
Log a sample
Dosing referenceCycle-length evidence
Unbranded reference vial illustrating Pentadeca arginate (PDA); not an actual product
Research reference, not advice. No administration data. Amiravo sells nothing; some links are referrals.Read the full notice

Key takeaways

  • No primary source documenting the identity of pentadeca arginate was located: PubMed, PubChem and ClinicalTrials.gov returned no records under the name or common variants 1,2,3.
  • Statements that PDA is an arginate salt of BPC-157, or a modified BPC-157, could not be confirmed from primary sources; if it were a salt of the same peptide, the active sequence would be BPC-157's GEPPPGKPADDAGLV 4.
  • No study of PDA itself in cells, animals or humans was located, so no PDA-specific finding can be reported 1,3.
  • Human evidence for BPC-157 itself is limited to three small, poor-quality studies, and no completed phase 2 trial was reported in a 2026 review 5,6.
  • BPC-157 is named in S0 of the 2026 Prohibited List; a substance marketed as a form of it would raise the same question, so status should be confirmed with the relevant anti-doping organization 8.

Development stage

Where Pentadeca arginate (PDA) sits between laboratory work and regulatory approval.

  1. Preclinical (current)
  2. Phase 1
  3. Phase 2
  4. Phase 3
  5. Approved

Stage comes from the regulatory record and ClinicalTrials.gov studies naming the compound (for compounds approved nowhere, only completed trials or trials with posted results count) (checked 2026-10-24). A registered trial is not a result.

Mechanism of action

No mechanistic study of a substance named pentadeca arginate was located 1.

What can and cannot be inferred

  • If PDA is a salt of BPC-157: a salt counter-ion (such as arginine, acetate or trifluoroacetate) would change formulation properties but not the peptide sequence; PubChem lists BPC-157 trifluoroacetate and free-base forms but no arginate 4.
  • If PDA is a modified sequence: no structure has been published, so neither BPC-157 data nor any other data can be assumed to apply.

Reviews of BPC-157 describe reported cytoprotective activity in animal models and note the lack of an approved formulation or validated human dosing 6.

Research overview

Human research

No human studies of pentadeca arginate were located 1,3. For comparison, a 2026 systematic review of BPC-157 identified a 16-person retrospective knee-pain study, a 12-person interstitial cystitis pilot and a 2-person intravenous pilot, all rated poor quality 5.

Animal research

No animal studies of pentadeca arginate were located 1.

In-vitro research

No in vitro studies of pentadeca arginate were located 1.

Key studies

  1. Poolton et al., Acta Orthop Belg (2026)
    PRISMA systematic review (PROSPERO-registered) of human BPC-157 studies, searched to 1 June 2026
    Model: Humans (3 studies, n = 30) - BPC-157, not PDA

    All three studies were judged poor quality and overall certainty very low; no PDA studies were included 5.

  2. Mateescu et al., Pharmaceutics (2026)
    Narrative review of BPC-157 pharmaceutical development
    Model: Literature review - BPC-157, not PDA

    Reported no approved formulation, no validated dosing regimen and no completed phase 2 trial for BPC-157 6.

  3. PubMed, PubChem and ClinicalTrials.gov searches (2026)
    Database searches for PDA names
    Model: Not applicable

    No records were returned for pentadeca arginate or its common name variants 1,2,3.

Published adverse-event data

Reported in the cited trials or product labels. Frequencies apply to the stated population and do not transfer to other settings.

Emerging safety signals

  • No human safety data on pentadeca arginate were located; FDA's concerns about BPC-157 (immunogenicity, peptide-related impurities and API characterization) cannot be assumed either to apply or not to apply to PDA because its composition is undocumented 1,7. 7 (2026)

What is not known: The chemical identity, sequence, counter-ion, purity standard, pharmacokinetics, human safety and any biological activity of pentadeca arginate are not documented in the primary sources reviewed 1,2,3. Whether it is chemically equivalent to BPC-157 is unknown 4.

Background viewing

We haven't found a clinician video focused on Pentadeca arginate (PDA) yet. Meanwhile, this widely watched talk covers the science of aging in general. It does not discuss Pentadeca arginate (PDA).

David Sinclair, PhD (Harvard Medical School) on the biology of aging
The Diary Of A CEO · 6.9M views · 2026

These creators are not affiliated with Amiravo and do not endorse Amiravo or any product linked on this site. Nothing here is medical advice. Video views counted on YouTube as of Oct 24, 2026.

Regulatory status

Status
Not approved by the FDA for any use; no FDA, PubMed, PubChem or ClinicalTrials.gov record under this name was located as of 2026-10-24 1,2,3,7.
United States (FDA)
No FDA approval or FDA document naming pentadeca arginate was located; FDA's compounding safety-risk page (current as of April 22, 2026) names BPC-157 but not PDA 7.
Sport (WADA)
Pentadeca arginate is not named individually in the 2026 Prohibited List text reviewed; S0 covers pharmacological substances with no current governmental approval for human therapeutic use and names BPC-157 as an example 8.

Status varies by country and changes over time. How we describe regulatory status.

Quality and testing notes

Because no reference structure is published, a certificate of analysis for material sold as PDA should state the full sequence, the counter-ion and its proportion, the mass-spectrometry identity result with expected mass, HPLC purity, endotoxin and net peptide content; without these, identity relative to BPC-157 (C62H98N16O22) cannot be judged [4].

How purity testing works · Reading a certificate of analysis

Check a Pentadeca arginate (PDA) certificate of analysis

Storage and handling

No product-specific stability data were located; follow the supplier's documentation for the lot.

Frequently asked questions

What is pentadeca arginate?
It is a commercial name; no peer-reviewed paper, PubChem record or registered trial defining its structure was located 1,2,3.
Is PDA the same as BPC-157?
This could not be confirmed. BPC-157 is a documented 15-residue peptide 4, but no primary source states that PDA has the same sequence.
Is PDA an arginate salt of BPC-157?
That description circulates, but PubChem lists BPC-157 free-base and trifluoroacetate forms and no arginate form, and no publication describing an arginate salt was located 1,4.
Are there studies on PDA?
None were located in PubMed or ClinicalTrials.gov as of 2026-10-24 1,3.
Is PDA FDA-approved?
No approval or FDA document naming it was located 7.
Is PDA allowed in sport?
It is not named individually in the 2026 list text reviewed; S0 covers non-approved substances and names BPC-157 8.

Latest indexed research

No new studies were filed in the last sweep.

Search all studies on Pentadeca arginate (PDA) (PubMed, Europe PMC, ClinicalTrials.gov)

Listed by publication type from the index record. Inclusion is not an endorsement; open the source to read the findings.

Revision history

Meaningful changes to this entry, with dates and sources. Last reviewed Oct 24, 2026. Typo and layout fixes are not listed.

  • New section· entryOct 24, 2026

    New research reference added: Pentadeca arginate (PDA).

References

  1. PubMed search for 'pentadeca arginate', 'pentadecapeptide arginate', 'pentadeca-arginate', 'BPC-157 arginate' and 'BPC 157 arginine salt' (0 records, searched 2026-10-24) PubMed (NCBI E-utilities). 2026
  2. PubChem name lookup for 'pentadeca arginate' and 'pentadecapeptide arginate' (no CID found, 2026-10-24) PubChem. 2026
  3. ClinicalTrials.gov search for 'pentadeca arginate' (no studies returned, 2026-10-24) ClinicalTrials.gov. 2026
  4. PubChem compound record for BPC-157 (CID 9941957) PubChem. 2026
  5. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety Acta Orthop Belg. 2026
  6. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Pharmaceutics. 2026
  7. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) FDA. 2026
  8. Tractatenblad 2026 Nr. 25: Anti-doping convention (ETS No. 135), amendment to the appendix - The 2026 Prohibited List, World Anti-Doping Code (English text; entry into force 1 January 2026) Tractatenblad van het Koninkrijk der Nederlanden (official government publication). 2026

Last reviewed October 24, 2026 by the Amiravo editorial team.

Read our editorial policy · Report an error on this page

Need the math?

Laboratory arithmetic with every formula shown.

For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page is educational and is not medical advice.

Unbranded reference vial illustrating Pentadeca arginate (PDA); not an actual product

Unbranded reference image. Amiravo does not produce, supply or sell this compound.

Specifications

Type
Single compound

Chemical identifiers are shown only when verified against PubChem.

Follow Pentadeca arginate (PDA)

See every new citation, evidence-grade or status change and correction in My Research, with optional email alerts. Free account.